Presentation (CTI)

OBJECTIVES: When the first orphan oncology Joint Clinical Assessment (JCA) under the EU HTA Regulation defined eight PICOs, how many could actually be answered? This case analysis examined the assessment of tovorafenib for paediatric low-grade glioma to quantify how much of an agreed scope a rare-disease evidence base can support.
METHODS: A structured case analysis examined the published JCA report against Regulation (EU) 2021/2282, Commission Implementing Regulation (EU) 2024/1381, and HTACG methodological guidance, alongside the developer dossier and the factual-accuracy record. Assessability was tracked PICO-by-PICO and outcome-by-outcome.
RESULTS: Of eight PICOs across three populations, only one produced a comparative result. That single answer rested on a surrogate endpoint (objective response rate), at an effective sample size of roughly six, and applied response criteria developed for high-grade disease to a low-grade indication. Patient-important outcomes — overall survival, quality of life, symptoms, and fatigue — were classified not assessable. The evidence derived from a single-arm study compared, without a common comparator, through unanchored indirect comparison. The practical consequence is that the JCA can enable national appraisal to begin without re-opening the clinical file, but cannot let it conclude on this evidence alone. The collapse was driven less by execution than by the structural limits of a rare paediatric evidence base.
CONCLUSIONS: An agreed scope is not an answerable one. When seven of eight questions return not assessable, the assessment documents the limits of rare-disease evidence more than the value of the medicine — a pattern future orphan JCAs and their scoping rules will need to anticipate.